Bicara Therapeutics Inc. (BCAX) - Uzoq muddatli qarzning kapitalga nisbati
Bicara Therapeutics Inc. (BCAX) rahbariyati investitsiyalarni jalb qilishda yuqori mahorat namoyish etmoqda va ficlatuzumab ishlab chiqilishi bo'yicha shaffof hisobotlarni yuritmoqda. 0.00 ko'rsatkichi aks etgan ushbu narxlar grafigi aktivning dinamikasini vizuallashtiradi. Ekspertlar jamoasi bosh va bo'yin o'smalari terapiyasi uchun innovatsiyalarni tijoriy joriy etishga e'tibor qaratgan bo'lib, jadal o'sishni ta'minlash maqsadida modda ishlab chiqarish va klinik sinovlarni to'liq tashqi pudratchilarga topshirgan.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_BCAX_-_Bicara-Therapeutics-Inc._-_Long-Term-Debt-to-Equity "bicara.com (BCAX): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 14.09.2024dan 31.10.2026gacha | 👁️GURU.Markets👁️")
Bicara Therapeutics Inc. kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Bicara Therapeutics Inc.|BCAX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati bicara.com|BCAX - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Bicara Therapeutics Inc.|BCAX - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Bicara Therapeutics|Tezkor likvidlik koeffitsiyenti bicara.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:Bicara Therapeutics Inc - BCAX
Bicara Therapeutics Inc. (BCAX) o'simta chidamliligiga qarshi kurashish uchun bifunksional antitelalarni ishlab chiqishga katta resurslar investitsiya qilmoqda. Uzoq muddatli kredit leverajini tahlil qilish bir yildan ortiq muddatga ega majburiyatlarning kapitalga nisbatini baholash imkonini beradi va bu esa R&D kengayishining qaysidir darajada qarz mablag'lariga bog'liqligini aniqlaydi. Ushbu ko'rsatkichning barqarorligi muvozanatli moliyaviy strategiyani va innovatsiyalarni kengaytirish jarayonida kompaniyaning qarz risklariga nisbatan chidamliligini tasdiqlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Personalis Inc (PSNL) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ERAS: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Delcath Corp (DCTH)|Uzoq muddatli qarzning o'z kapitaliga nisbati Y-mAbs Therapeutics|AURA: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati SLS (SELLAS Life Sciences Group)|ACTU - Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning kapitalga nisbati CSBR|Uzoq muddatli qarzning o'z kapitaliga nisbati XBIT (xbiotech.com)|Uzoq muddatli qarzning kapitalga nisbati CVM (CEL-SCI)|Uzoq muddatli qarzdorlikning kapitalga nisbati OS Therapies Inc. (OSTX)|Radiopharm Theranostics Limited - Uzoq muddatli qarzning kapitalga nisbati|Artiva Biotherapeutics, Inc. (ARTV) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ANL: Uzoq muddatli qarzning kapitalga nisbati|verupharma.com (VERU) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Tempest Therapeutics, Inc.|XLO: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati RENB|Uzoq muddatli qarzning kapitalga nisbati muraloncology.com (MURA)|Kairos Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti OKUR|GDTC: Uzoq muddatli qarzning o'z kapitaliga nisbati|Curis, Inc. - Uzoq muddatli kreditlarning kapitalga nisbati|APLM: Uzoq muddatli qarzning kapitalga nisbati|Tharimmune Corporation - Uzoq muddatli qarzning kapitalga koeffitsiyenti|ADVB (Advanced Biomed Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati genprex.com GNPX|Uzoq muddatli qarzning o'z kapitaliga nisbati Calidi Biotherapeutics (CLDI)|SBFM (Sunshine Biopharma Inc.) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati XBIO (Xenetic Biosciences, Inc.)|Uzoq muddatli qarzning kapitalga nisbati Salarius Pharma SLRX|PPBT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati AONC|BGNE: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Checkpoint Therapeutics Inc. (CKPT)|Uzoq muddatli qarzning o'z kapitaliga nisbati ELEV|Uzoq muddatli qarzning kapitalga nisbati iCAD Corp|Uzoq muddatli qarzning o'z kapitaliga nisbati IKNA (Ikena Oncology, Inc.)|Uzoq muddatli kreditlarning kapitalga nisbati NTBL|Uzoq muddatli qarzning kapitalga nisbati VIRX (Viracta Therapeutics, Inc.)|Uzoq muddatli qarzdorlikning kapitalga nisbati MorphoSys Inc (MOR)|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Ascentage (AAPGV) - Uzoq muddatli qarzning o'z kapitaliga nisbati